Akitsu Hotta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3650106/publications.pdf

Version: 2024-02-01

73 papers	6,112 citations	101496 36 h-index	85498 71 g-index
77 all docs	77 docs citations	77 times ranked	9300 citing authors

#	Article	IF	Citations
1	Stage-Specific Optimization of Activin/Nodal and BMP Signaling Promotes Cardiac Differentiation of Mouse and Human Pluripotent Stem Cell Lines. Cell Stem Cell, 2011, 8, 228-240.	5.2	1,034
2	Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9. Stem Cell Reports, 2015, 4, 143-154.	2.3	459
3	Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell, 2019, 24, 566-578.e7.	5.2	356
4	Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nature Methods, 2009, 6, 370-376.	9.0	274
5	Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Human Molecular Genetics, 2011, 20, 2103-2115.	1.4	241
6	Direct Comparison of Autologous and Allogeneic Transplantation of iPSC-Derived Neural Cells in the Brain of a Nonhuman Primate. Stem Cell Reports, 2013, 1, 283-292.	2.3	233
7	Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nature Communications, 2020, 11, 1334.	5.8	197
8	Hair Follicle Dermal Stem Cells Regenerate the Dermal Sheath, Repopulate the Dermal Papilla, and Modulate Hair Type. Developmental Cell, 2014, 31, 543-558.	3.1	189
9	Efficient and Reproducible Myogenic Differentiation from Human iPS Cells: Prospects for Modeling Miyoshi Myopathy In Vitro. PLoS ONE, 2013, 8, e61540.	1.1	188
10	The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	182
11	Retroviral vector silencing during iPS cell induction: An epigenetic beacon that signals distinct pluripotent states. Journal of Cellular Biochemistry, 2008, 105, 940-948.	1.2	142
12	Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. Cell Reports, 2016, 15, 2301-2312.	2.9	141
13	Constitutive heterochromatin reorganization during somatic cell reprogramming. EMBO Journal, 2011, 30, 1778-1789.	3.5	134
14	Focal Transplantation of Human iPSC-Derived Glial-Rich Neural Progenitors Improves Lifespan of ALS Mice. Stem Cell Reports, 2014, 3, 242-249.	2.3	131
15	CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. Nature Communications, 2019, 10, 5302.	5.8	127
16	From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing. Annual Review of Genetics, 2015, 49, 47-70.	3.2	111
17	Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. Cell Stem Cell, 2018, 23, 850-858.e4.	5.2	110
18	Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nature Communications, 2021, 12, 7101.	5.8	100

#	Article	IF	Citations
19	Tissue-Engineered Vascular Grafts with Advanced Mechanical Strength from Human iPSCs. Cell Stem Cell, 2020, 26, 251-261.e8.	5.2	96
20	Cell-type-specific genome editing with a microRNA-responsive CRISPRâ€“Cas9 switch. Nucleic Acids Research, 2017, 45, e118-e118.	6.5	88
21	Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. Journal of Controlled Release, 2022, 342, 345-361.	4.8	82
22	EOS lentiviral vector selection system for human induced pluripotent stem cells. Nature Protocols, 2009, 4, 1828-1844.	5.5	75
23	InÂVitro Disease Modeling of Hermansky-Pudlak Syndrome Type 2ÂUsing Human Induced Pluripotent Stem Cell-Derived Alveolar Organoids. Stem Cell Reports, 2019, 12, 431-440.	2.3	71
24	Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nature Biomedical Engineering, 2021, 5, 429-440.	11.6	70
25	Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. Scientific Reports, 2016, 6, 34904.	1.6	67
26	MECP2 Isoform-Specific Vectors with Regulated Expression for Rett Syndrome Gene Therapy. PLoS ONE, 2009, 4, e6810.	1.1	66
27	iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports, 2020, 14, 49-59.	2.3	57
28	Efficient genomic correction methods in human iPS cells using CRISPRâ€“Cas9 system. Methods, 2016, 101, 27-35.	1.9	54
29	A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4. Human Molecular Genetics, 2018, 27, 4024-4035.	1.4	49
30	PKD1-Dependent Renal Cystogenesis in Human Induced Pluripotent Stem Cell-Derived Ureteric Bud/Collecting Duct Organoids. Journal of the American Society of Nephrology: JASN, 2020, 31, 2355-2371.	3.0	47
31	Delivery of Full-Length Factor VIII Using a piggyBac Transposon Vector to Correct a Mouse Model of Hemophilia A. PLoS ONE, 2014, 9, e104957.	1.1	44
32	Ataxia-telangiectasia mutated (ATM) deficiency decreases reprogramming efficiency and leads to genomic instability in iPS cells. Biochemical and Biophysical Research Communications, 2011, 407, 321-326.	1.0	40
33	Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells. Scientific Reports, 2013, 3, 1978.	1.6	40
34	Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. Experimental Hematology, 2015, 43, 849-857.	0.2	40
35	A novel ADPKD model using kidney organoids derived from disease-specific human iPSCs. Biochemical and Biophysical Research Communications, 2020, 529, 1186-1194.	1.0	38
36	Genetic correction using engineered nucleases for gene therapy applications. Development Growth and Differentiation, 2014, 56, 63-77.	0.6	37

#	Article	IF	Citations
37	Srf destabilizes cellular identity by suppressing cell-type-specific gene expression programs. Nature Communications, 2018, 9, 1387.	5.8	35
38	Dual inhibition of TMPRSS2 and Cathepsin B prevents SARS-CoV-2 infection in iPS cells. Molecular Therapy - Nucleic Acids, 2021, 26, 1107-1114.	2.3	35
39	Transplantation of neurons derived from human iPS cells cultured on collagen matrix into guinea-pig cochleae. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 1766-1778.	1.3	34
40	Reprogramming progeria fibroblasts reâ€establishes a normal epigenetic landscape. Aging Cell, 2017, 16, 870-887.	3.0	34
41	Induced Fetal Human Muscle Stem Cells with High Therapeutic Potential in a Mouse Muscular Dystrophy Model. Stem Cell Reports, 2020, 15, 80-94.	2.3	31
42	Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy. Stem Cells International, 2017, 2017, 1-11.	1.2	30
43	Production of anti-prion scFv-Fc fusion proteins by recombinant animal cells. Journal of Bioscience and Bioengineering, 2003, 95, 231-238.	1.1	29
44	Retrovirus Silencing by an Epigenetic TRIM. Cell, 2007, 131, 13-14.	13.5	29
45	Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases. International Journal of Molecular Sciences, 2015, 16, 24751-24771.	1.8	28
46	Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress. Stem Cell Reports, 2018, 10, 1835-1850.	2.3	28
47	Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein. Stem Cell Reports, 2021, 16, 985-996.	2.3	28
48	Characterization of hiPSC-Derived Muscle Progenitors Reveals Distinctive Markers for Myogenic Cell Purification Toward Cell Therapy. Stem Cell Reports, 2021, 16, 883-898.	2.3	26
49	Sall1 transiently marks undifferentiated heart precursors and regulates their fate. Journal of Molecular and Cellular Cardiology, 2016, 92, 158-162.	0.9	23
50	A Î²1-tubulinâ€“based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production. Blood Advances, 2018, 2, 2262-2272.	2.5	23
51	Comprehensive chemical secretory measurement of single cells trapped in a micro-droplet array with mass spectrometry. RSC Advances, 2015, 5, 16968-16971.	1.7	22
52	Site-specific randomization of the endogenous genome by a regulatable CRISPR-Cas9 piggyBac system in human cells. Scientific Reports, 2018, 8, 310.	1.6	22
53	Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles. Biochemical and Biophysical Research Communications, 2018, 505, 1097-1102.	1.0	21
54	Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application. Molecular Therapy - Methods and Clinical Development, 2022, 26, 15-25.	1.8	20

#	Article	IF	Citations
55	Characterization of transient expression system for retroviral vector production. Journal of Bioscience and Bioengineering, 2006, 101, 361-368.	1.1	19
56	A muscle fatigue-like contractile decline was recapitulated using skeletal myotubes from Duchenne muscular dystrophy patient-derived iPSCs. Cell Reports Medicine, 2021, 2, 100298.	3.3	17
57	An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development. Stem Cell Reports, 2016, 6, 592-606.	2.3	16
58	Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells. Methods in Molecular Biology, 2018, 1828, 191-217.	0.4	16
59	Human AK2 links intracellular bioenergetic redistribution to the fate of hematopoietic progenitors. Biochemical and Biophysical Research Communications, 2018, 497, 719-725.	1.0	15
60	MAGI-2 orchestrates the localization of backbone proteins in the slit diaphragm of podocytes. Kidney International, 2021, 99, 382-395.	2.6	15
61	Genome Editing Gene Therapy for Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2015, 2, 343-355.	1.1	14
62	Production of anti-CD2 chimeric antibody by recombinant animal cells. Journal of Bioscience and Bioengineering, 2004, 98, 298-303.	1.1	10
63	Expression dynamics of HAND1/2 in inÂvitro human cardiomyocyte differentiation. Stem Cell Reports, 2021, 16, 1906-1922.	2.3	9
64	Î²-Globin LCR and Intron Elements Cooperate and Direct Spatial Reorganization for Gene Therapy. PLoS Genetics, 2008, 4, e1000051.	1.5	8
65	Optimized electroporation of CRISPR-Cas9/gRNA ribonucleoprotein complex for selection-free homologous recombination in human pluripotent stem cells. STAR Protocols, 2021, 2, 100965.	0.5	8
66	Contractile Activity of Myotubes Derived from Human Induced Pluripotent Stem Cells: A Model of Duchenne Muscular Dystrophy. Cells, 2021, 10, 2556.	1.8	4
67	YY1 binds to regulatory element of chicken lysozyme and ovalbumin promoters. Cytotechnology, 2007, 52, 159-170.	0.7	2
68	Generation of a transgene-free iPSC line and genetically modified line from a facioscapulohumeral muscular dystrophy type 2 (FSHD2) patient with SMCHD1 p.Lys607Ter mutation. Stem Cell Research, 2020, 47, 101884.	0.3	2
69	Development of alternative gene transfer techniques for exÂvivo and inÂvivo gene therapy in a canine model. Regenerative Therapy, 2021, 18, 347-354.	1.4	2
70	Natural Killer Cell Activities Against iPSCs-Derived HLA-Knockout Platelets and Megakaryocytes Reveal Perfect Rejection Profiles for Allotransfusion. Blood, 2016, 128, 3841-3841.	0.6	2
71	Editing Cultured Human Cells: From Cell Lines to iPS Cells. , 2015, , 45-69.		1
72	Induced pluripotent stem cells. , 0, , 19-33.		0

#	Article	IF	Citations
73	Chemical Control of iPS Cells. Trends in the Sciences, 2011, 16, 62-65.	0.0	0